Max S. Topp

Max S. Topp is a leading clinical investigator in blinatumomab development who has shaped understanding of BiTE therapy through pivotal MRD and efficacy studies. As Head of Hematology at University Hospital Würzburg, he led BLAST trial investigations demonstrating blinatumomab's ability to convert MRD-positive to MRD-negative status. His senior authorship on the TOWER trial (NEJM 2017) established blinatumomab's superiority over chemotherapy for relapsed ALL. With 339 publications and 20,060+ citations, Topp continues advancing BiTE therapy optimization through dosing and combination strategies.

Max S. Topp博士是blinatumomab开发的领先临床研究者，通过关键的MRD和疗效研究塑造了对BiTE疗法的理解。作为维尔茨堡大学医院血液科主任，他领导了BLAST试验研究，证明blinatumomab能够将MRD阳性转化为MRD阴性状态。他作为TOWER试验（NEJM 2017）的高级作者，确立了blinatumomab对复发ALL优于化疗。凭借339篇出版物和20,060+次引用，Topp继续通过剂量和联合策略推进BiTE疗法优化。